Collegium Pharmaceutical (COLL) Convertible Debt (2020 - 2026)

Collegium Pharmaceutical has reported Convertible Debt for 7 years, with the latest figure at $238.7 million in Q2 2026.

• On a quarterly basis, Convertible Debt changed 0.44% year-over-year to $238.7 million in Q2 2026; TTM through Jun 2026 was $238.7 million, a 0.44% change from a year earlier, with the FY2025 full-year figure at $238.2 million, changed 0.44% from the prior year.
• Convertible Debt was $238.7 million for Q2 2026 at Collegium Pharmaceutical, roughly flat from $238.5 million in the prior quarter.
• The five-year high for Convertible Debt was $262.4 million in Q1 2024, with the low at $140.2 million in Q1 2022.
• Average Convertible Debt over 5 years is $222.8 million, with a median of $237.8 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Convertible Debt soared 86.34% in 2023, then dropped 9.53% in 2025.
• Over 5 years, Convertible Debt stood at $140.9 million in 2022, then jumped by 86.07% to $262.1 million in 2023, then declined by 9.52% to $237.2 million in 2024, then gained by 0.44% to $238.2 million in 2025, then gained by 0.22% to $238.7 million in 2026.
• The last three Convertible Debt figures came in at $238.7 million (Q2 2026), $238.5 million (Q1 2026), and $238.2 million (Q4 2025), per Business Quant data.